Back to today’s briefing

Story perspectives

FDA Approves Controversial Non-Addictive Painkiller Journavx

3/20/2025

29 6

Summary

Story summary

On January 30, 2025, the FDA greenlit Journavx, a painkiller touted as non-addictive. While it offers hope for those vulnerable to addiction, experts caution about the absence of long-term safety data. Questions linger over its affordability and possible side effects, alongside uncertainty regarding its effectiveness across different populations.

1 of 1

Story summary

On January 30, 2025, the FDA greenlit Journavx, a painkiller touted as non-addictive. While it offers hope for those vulnerable to addiction, experts caution about the absence of long-term safety data. Questions linger over its affordability and possible side effects, alongside uncertainty regarding its effectiveness across different populations.